Results of FDA study supports development of high throughput sequencing for viral safety evaluation of biologic materials
The findings of a study led by scientists at the U.S. Food and Drug Administration (FDA) suggest that a highly sensitive, but complex, new technology to sequence the genetic material of viruses could be standardized and used for rapid screening of biologic products, including vaccines, to demonstrate absence of contamination.
No hay comentarios:
Publicar un comentario